TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36035961
Drug: Higher magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher magnesium intake (>320 mg/day)
Study: 36035961
Drug: Higher magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher magnesium intake (>320 mg/day) in diuretic users
Study: 36036663
Drug: Fresh solution
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh solution exchange
Study: 36036663
Drug: Reuse of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reuse of original solution
Study: 36036971
Drug: Set Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Set Daily Reminders
Study: 36037793
Drug: Pain ratings
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain ratings and the amount of opioid analgesics consumed after the first and second TKAs
Study: 36038699
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of 0.9% saline over 30 min on two consecutive days
Study: 36041227
Drug: Oral microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral microbiota assessment
Study: 36041755
Drug: Any antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antiarrhythmic therapies (AATs) including cardioversion, catheter ablation, and fulfilled antiarrhythmic drug (AAD) prescription.
Study: 36042527
Drug: Induced hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced hypertension treatment
Study: 36043184
Drug: 30 μg of
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 μg of SCB-2019 + CpG + aluminium hydroxide
Study: 36043184
Drug: SCB-2019 formulations
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 formulations
Study: 36043728
Drug: French version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: French version of the Bath Ankylosing Spondylitis Global score (BAS-G)
Study: 36044285
Drug: Unhealthy alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unhealthy alcohol use (AUDIT-C ≥3 for women or ≥4 for men; PEth ≥50 ng/mL)
Study: 36044285
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol use (AUDIT-C 1-2 for women or 1-3 for men; PEth 8 ≥ 50 ng/mL)
Study: 36044285
Drug: No alcohol
Normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alcohol consumption (self-report and PEth <8 ng/mL)
Study: 36044385
Drug: TMTV/Eastern Cooperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMTV/Eastern Cooperative Oncology Group-PS combination
Study: 36044388
Drug: Tisagenlecleucel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisagenlecleucel plus pembrolizumab (200 mg every 21 days for up to 6 doses)
Study: 36044526
Drug: Atezolizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1,200 mg) plus Bevacizumab (7.5 mg/kg) administered every 3 weeks
Study: 36044870
Drug: Lanreotide autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel (LAN) 120 mg every 28 days and temozolomide (TMZ) 250 mg/day for 5 consecutive days every 28-day cycle
Study: 36045316
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid 500 mg three times daily
Study: 36046613
Drug: Sick-day protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sick-day protocol administered via interactive voice response system (IVRS)
Study: 36048266
Drug: Consolidation durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation durvalumab immune checkpoint inhibitor (ICI) therapy
Study: 36048266
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of COPD with perfused lung radiomics size features
Study: 36048266
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of COPD with perfused lung radiomics shape features
Study: 36048535
Drug: Olaparib in
Normalized name: Product containing olaparib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib in combination with buparlisib (BKM120)
Study: 36048970
Drug: Nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogue (NA) therapy withdrawal
Study: 36049654
Drug: Rezivertinib (BPI-7711)
Normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezivertinib (BPI-7711) at 180 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: 36050737
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of noradrenaline
Study: 36050804
Drug: Perioperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative oral nutritional support (ONS)
Study: 36050896
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion block (SGB) combined with prolonged exposure therapy (PE)
Study: 36051040
Drug: Dose-dense immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense immunochemotherapy with early systemic CNS prophylaxis
Study: 36051045
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg by mouth once daily in four-week cycles for up to 24 cycles
Study: 36052502
Drug: Enzalutamide, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide, a second-generation AR-targeted therapy
Study: 36052732
Drug: Morreton virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morreton virus (MORV) at a dose of 1 × 10 7 TCID 50
Study: 36052732
Drug: Morreton virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morreton virus (MORV) at a dose of 10 10 TCID 50
Study: 36052732
Drug: Vesicular stomatitis
Normalized name: Vesicular stomatitis virus Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesicular stomatitis virus (VSV) at a dose of 1 × 10 8 TCID 50
Study: 36053449
Drug: Extended regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended regimen of ethinylestradiol/drospirenone (EE/DRSP) taken daily for up to 120 consecutive days
Study: 36053558
Drug: Web-based decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based decision aid (DA) for treatment planning of SKMs
Study: 36053624
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) in the first postnatal week
Study: 36053632
Drug: Ibuprofen (n=3857)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (n=3857)
Study: 36053632
Drug: Overall PDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall PDA treatment (n=5721)
Study: 36054234
Drug: pp65-specific TCR-T
Normalized name: Neoantigen specific TCR-T cell therapy
DrugBank: Neoantigen specific TCR-T cell therapy (DB17458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pp65-specific TCR-T cell therapy
Study: 36054490
Drug: CV301 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV301 in combination with nivolumab (C1)
Study: 36054490
Drug: CV301 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV301 in combination with pembrolizumab (C2)
Study: 36055922
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of triamcinolone acetonide
Study: 36055962
Drug: Dietary acrylamide
Normalized name: acrylamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary acrylamide intake (mean ± SD: 30.1 ± 21.9 µg/d)
Study: 36057175
Drug: Astra-Zeneca vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astra-Zeneca vaccine and Sputnik V vaccine (complete vaccination)
Study: 36057544
Drug: IgM(N) antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM(N) antibody levels in infected healthcare workers
Study: 36057544
Drug: IgG(N) antibody
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG(N) antibody levels in infected healthcare workers
Study: 36057544
Drug: IgG(S) antibody
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG(S) antibody levels in infected healthcare workers
Study: 36057544
Drug: Kinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetics of IgM(N) and IgG(N) antibodies
Study: 36057544
Drug: Kinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetics of IgG(S) antibodies
Study: 36057544
Drug: Kinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetics of IgM and IgG antibodies
Study: 36058111
Drug: Community sanitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community sanitation coverage of at least one latrine per compound within 50m
Study: 36058810
Drug: Biomarker use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker use in treatment decisions
Study: 36058925
Drug: Concentrated transdiagnostic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated transdiagnostic, interdisciplinary group treatment delivered during 5 consecutive days.
Study: 36059138
Drug: Ceftaroline 600
Normalized name: ceftaroline 600 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline 600 mg every 12 hours
Study: 36059138
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of ceftaroline 50 mg/h after a loading dose of 600 mg
Study: 36059450
Drug: Neoadjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunotherapy (24 patients)
Study: 36059450
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (16 patients)
Study: 37655106
Drug: Neoadjuvant targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant targeted therapy (9 patients)
Study: 36060221
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A supplements and vitamin A-fortified foods
Study: 36061336
Drug: Aficamten (≤50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (≤50 mg single doses or ≤10 mg daily for 14 or 17 days)
Study: 36061421
Drug: Trans-obturator tape
Normalized name: TAPE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-obturator tape intervention, details on dosage and duration not available
Study: 36061598
Drug: 4-day accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day accelerated continuous theta burst stimulation (cTBS) treatment
Study: 36062026
Drug: Natalizumab followed
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab followed by alemtuzumab sequential therapy
Study: 36062451
Drug: Remote patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote patient management (RPM) with daily measurements of vital parameters under guidance of HF nurses.
Study: 36062451
Drug: Remote patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote patient management (RPM) with daily measurements of vital parameters.
Study: 36063533
Drug: Oral testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testing and provider-assisted confidential partner notification.
Study: 36064386
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg) plus docetaxel (75 mg/m2)
Study: 36064670
Drug: IPV-Al (aluminium-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV-Al (aluminium-adjuvanted reduced dose inactivated polio vaccine)
Study: 36064725
Drug: Miglustat use
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Miglustat use (a glucosylceramide synthase inhibitor)
Study: 36064748
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery for treatment (GIFT) - a brief, two-session guided imagery intervention.
Study: 36064748
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) - control group.
Study: 36066745
Drug: Odevixibat treatment
Normalized name: Odevixibat
DrugBank: Odevixibat (DB16261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Odevixibat treatment for 24 weeks
Study: 36066903
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse 15 mg/kg/day for 3 days followed by oral prednisone 1 mg/kg/day
Study: 36066903
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 1 mg/kg/day alone
Study: 36067063
Drug: Daratumumab subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab subcutaneous (DARA SC) 1800 mg every 4 weeks
Study: 36067139
Drug: Physiotherapy interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy interventions recommended by physiotherapists (education, spinal exercises, manual therapy)
Study: 36067139
Drug: Passive physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passive physiotherapy approaches prescribed by general practitioners (massage therapy, electrotherapy)
Study: 36068495
Drug: FOLFOXIRI (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) administered for six two-weekly cycles prior to chemoradiotherapy.
Study: 36068858
Drug: Vortioxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine treatment for MDD (6 months)
Study: 36068950
Drug: Bispecific LV20.19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific LV20.19 CAR T-cell therapy at a target dose of 2.5 × 10^6 cells/kg
Study: 36069336
Drug: Pan-enteric capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pan-enteric capsule endoscopy (CE)
Study: 36069495
Drug: rFSH (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFSH (150 IU daily)
Study: 36070176
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated split-virion influenza vaccine (QIV; Vaxigrip Tetra)
Study: 36070539
Drug: UCPVax (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCPVax (0.25 mg, 0.5 mg, and 1 mg)
Study: 36070540
Drug: Pafolacianine (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging
Study: 36072945
Drug: Analytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analytic treatment interruption (ATI)
Study: 36072994
Drug: Burosumab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burosumab (0.3, 0.6, or 1.0 mg/kg subcutaneous injection every 4 weeks, titrated at Week 12)
Study: 36073648
Drug: Serum drug
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum drug measurements
Study: 36073648
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed therapy
Study: 36074550
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (5 times/week)
Study: 36074550
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1 time/week)
Study: 36075501
Drug: CC criteria
Normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC criteria for PEP
Study: 36075560
Drug: Scout Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scout Dose Resin Yttrium-90 Microspheres
Study: 36076205
Drug: Therapeutic Assertive
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Assertive Community Treatment
Study: 36077617
Drug: BMS-986158 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986158 (5 days on, 2 days off; 0.75-4.5 mg)
Study: 36077617
Drug: BMS-986158 (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986158 (14 days on, 7 days off; 2.0-3.0 mg)
Study: 36077617
Drug: BMS-986158 (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986158 (7 days on, 14 days off; 2.0-4.5 mg)
Study: 36078407
Drug: Waist girth-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waist girth-based equations (e.g., relative fat mass)
Study: 36081609
Drug: Mind-body medicine
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body medicine (MBM) program, weekly 6-h session for 10 weeks
Study: 36081814
Drug: EA plus
Normalized name: Finacea Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA plus high-dose DCPA (4 mg)
Study: 36081814
Drug: EA plus
Normalized name: Finacea Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA plus low-dose DCPA (2 mg)
Study: 36082269
Drug: Tafamidis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis treatment for 24 months
Study: 36082554
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (NHA) prior to radical prostatectomy (RP)
Study: 36082616
Drug: ONO-4578, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-4578, an antagonist of prostaglandin E, specific dosage and duration not available
Study: 36083035
Drug: Chemotherapy (anthracycline-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (anthracycline-containing regimens)
Study: 36083129
Drug: AVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine)
Study: 36083129
Drug: Sequential pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pembrolizumab and AVD
Study: 36083174
Drug: Comorbidity count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comorbidity count (CC)
Study: 36083313
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus autologous dendritic cell vaccine
Study: 36083982
Drug: Second tertile
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second tertile of baseline plasma Se (74.5 to < 89.4 μg/L)
Study: 36083982
Drug: Highest tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest tertile of baseline plasma Se (89.4 to <150 μg/L)
Study: 36084395
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg, administered intravenously every 3 weeks
Study: 36084396
Drug: eprenetapopt (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: eprenetapopt (4.5 g/day IV on days 1-4) plus pembrolizumab (200 mg IV on day 3 in each 21-day cycle)
Study: 36085059
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin A
Study: 36085337
Drug: PROMs questionnaires
Normalized name: MENTHOL 5.5 g in 100 g / BORNEOL 6.25 g in 100 g / CINNAMOMUM CAMPHORA LEAF 12.5 g in 100 g / BARLERIA LUPULINA WHOLE 12.5 g in 100 g TOPICAL PATCH [Wang Prom Green Balm by Wang Prom]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROMs questionnaires (Euro Quality 5 Dimensions 3L, EQ-5D-3L, Euro-Quality-Visual-Analytic-Score, EQ-VAS, Hip disability and Osteoarthritis Outcome Score, HOOS-PS) administered pre-operatively, at 6 months, and at 12 months after surgery.
Study: 36087148
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers
Study: 36087223
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for GERD
Study: 36088907
Drug: Drug-Induced Acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Induced Acute Kidney Injury (DI-AKI) risk prediction models
Study: 36088907
Drug: Statistical methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical methods (e.g., least absolute shrinkage and selection operator regression, advanced machine learning techniques)
Study: 36089112
Drug: GST-HG131, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG131, a novel HBV antigen inhibitor
Study: 36089578
Drug: UV1 vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV1 vaccination and ipilimumab treatment
Study: 36089621
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (APT) + Oral anticoagulation (OAC)
Study: 36090637
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus cisplatin (Pem-Cis); 500 mg/m2 of pemetrexed administered for four cycles in 99 patients (94.3%).
Study: 36092320
Drug: Erlotinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib and proton therapy
Study: 36093342
Drug: Single fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fraction of high-dose rate brachytherapy (HDB) 20 Gy